BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Solve ME/CFS Initiative - ECPv6.15.17//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Solve ME/CFS Initiative
X-ORIGINAL-URL:https://solvecfs.org
X-WR-CALDESC:Events for Solve ME/CFS Initiative
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260416T083000
DTEND;TZID=America/Los_Angeles:20260416T093000
DTSTAMP:20260716T053743
CREATED:20260225T175057Z
LAST-MODIFIED:20260401T190628Z
UID:43385-1776328200-1776331800@solvecfs.org
SUMMARY:GLP-1 Drugs to Reduce Symptoms in People with ME/CFS and Identify Disease Subgroups
DESCRIPTION:Glucagon-Like Peptide-1 (GLP-1) agonist medications\, like semaglutide\, are injectable or oral drugs that mimic the natural GLP-1 hormone\, which helps regulate insulin levels. Thus\, these medicines help control blood sugar in people with Type 2 diabetes and promote substantial weight loss for individuals with a high body mass index (BMI) by slowing digestion\, reducing appetite\, and increasing insulin release. \n\nBut can they also ease symptoms in people with ME/CFS and identify disease subtypes?\n\nSolve Ramsay Research Grant Program alum Dr. Carmen Scheibenbogen (acting director of the Institute for Medical Immunology of the Charité University Hospital in Berlin) recently received a Solve ME/CFS Catalyst Award for her study evaluating whether semaglutide reduces symptoms and improves quality of life for people with ME/CFS who have high BMI.\n\nIn this free educational webinar hosted by Solve Chief Scientific Officer Dr. Sadie Whittaker and VP of Scientific Programs Dr. Jessica Maya\, Dr. Scheibenbogen will discuss details of her study\, explain how her research will identify biomarkers\, and discuss how these results could help determine which patients are most likely to benefit from treatment.
URL:https://solvecfs.org/event/glp-1-drugs-to-reduce-symptoms-in-people-with-me-cfs-and-identify-disease-subgroups/
CATEGORIES:Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2026/02/ScheibenbogenMayaWhittakerTw.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260428T150000
DTEND;TZID=America/Los_Angeles:20260428T160000
DTSTAMP:20260716T053743
CREATED:20260225T175319Z
LAST-MODIFIED:20260227T012933Z
UID:43389-1777388400-1777392000@solvecfs.org
SUMMARY:The Discovery of Target Antigens for Dysfunctional T Cells in ME/CFS and Long COVID
DESCRIPTION:Dr. Liisa Selin\, Dr. Ayano Kohlgruber\, and Dr. Roshan Kumar received a Solve ME/CFS Catalyst Award for their study searching for the exact proteins recognized by T-cell receptors from a person with ME/CFS and a person with Long Covid. \nThese disease-associated T cells include “exhausted” CD8+ T cells and “double-positive” CD4+/CD8+ T cells (which are found in people with autoimmune diseases\, too). The researchers hypothesize that these T cells recognize fragments of microbial proteins critical for developing the disease. The microbial protein fragments may overstimulate and exhaust the T cells. \nAlso\, fragments of human proteins may resemble these microbial protein fragments; thus\, the disease-associated T cells may cross-react with human proteins to drive an autoimmune response. \nIn this study\, the research team will screen a library of protein fragments from microbes (viruses and bacteria) that are associated with developing Long Covid or ME/CFS (e.g.\, SARS-CoV-2\, B. burgdorferi\, enteroviruses)\, and a library of protein fragments from humans (to find self-antigens). \nIf successful\, these deliverables would be important for understanding how much persisting pathogens or self-antigens can exhaust the immune system\, and how dysfunctional and exhausted immune responses contribute to ME/CFS and Long Covid. \nIn this webinar hosted by Solve M.E. VP of Scientific Programs Dr. Jessica Maya\, the panelists will discuss the study and how this work could also produce new disease biomarkers and suggest new treatments for patient subgroups\, as well as how the libraries of human leukocyte antigen–displayed microbial and human protein fragments established by this work could be valuable resources for future ME/CFS and Long Covid studies.
URL:https://solvecfs.org/event/the-discovery-of-target-antigens-for-dysfunctional-t-cells-in-me-cfs-and-long-covid/
CATEGORIES:Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2026/02/SelinSolveWebinarApril282026JMFinal-1.png
END:VEVENT
END:VCALENDAR